WESTMINSTER, Colo., March 27, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced management will participate in the upcoming 23rd Annual Needham Virtual Healthcare Conference. Management will be presenting on Wednesday, April 10th, 2024 at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time.
A live webcast of the event, as well as an archived recording will be available on the “Investors” section of the company’s website at: www.zimvie.com. The webcast will be archived and available for replay for at least 90 days after the event.
About ZimVie
ZimVie is a global life sciences leader in the dental and spine markets that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to treat a wide range of spine pathologies and support dental tooth replacement and restoration procedures. In March 2022 the company became an independent, publicly traded spin-off of the dental and spine business units of Zimmer Biomet to breathe new life, dedicated energy, and strategic focus to its portfolio of trusted brands and products. From its headquarters in Westminster, Colorado, and additional facilities around the globe, the company serves customers in over 70 countries worldwide with a robust offering of dental and spine solutions including differentiated product platforms supported by extensive clinical evidence. For more information about ZimVie, please visit us at www.ZimVie.com. Follow @ZimVie on Twitter, Facebook, LinkedIn, or Instagram.
Media Contact Information:
ZimVie
Laura Driscoll • This email address is being protected from spambots. You need JavaScript enabled to view it.
(774) 284-1606
Investor Contact Information:
Gilmartin Group LLC
Marissa Bych • This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$9.44 |
Daily Change: | 0.29 3.17 |
Daily Volume: | 127,175 |
Market Cap: | US$260.540M |
February 26, 2025 January 30, 2025 October 30, 2024 October 29, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load